Triphasil-21 and Oral candidiasis - a phase IV clinical study of FDA data

Summary:

Oral candidiasis is found among people who take Triphasil-21, especially for people who are female, 40-49 old.

The phase IV clinical study analyzes which people take Triphasil-21 and have Oral candidiasis. It is created by eHealthMe based on reports of 530 people who have side effects when taking Triphasil-21 from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 05, 2023

530 people reported to have side effects when taking Triphasil-21.
Among them, 9 people (1.7%) have Oral candidiasis.

What is Triphasil-21?

Triphasil-21 has active ingredients of ethinyl estradiol; levonorgestrel. eHealthMe is studying from 533 Triphasil-21 users for its effectiveness, alternative drugs and more.

What is Oral candidiasis?

Oral candidiasis (fungal infection of mouth) is found to be associated with 1,747 drugs and 1,151 conditions by eHealthMe.

Number of Triphasil-21 and Oral candidiasis reports submitted per year:

Could Triphasil-21 cause Oral candidiasis?

Gender of people who have Oral candidiasis when taking Triphasil-21 *:

female: 100 %
male: 0.0 %

Age of people who have Oral candidiasis when taking Triphasil-21 *:

Common drugs people take besides Triphasil-21 *:

Common side effects people have besides Oral candidiasis *:

Osteonecrosis Of Jaw (death of bone of jaw): 8 people, 88.89%
Bone Disorder: 8 people, 88.89%
Tooth Loss: 8 people, 88.89%
Dental Caries: 7 people, 77.78%
Toothaches (tooth pain): 7 people, 77.78%
Periodontal Disease (disease that attacks the gum and bone and around the teeth): 7 people, 77.78%
Impaired Healing: 7 people, 77.78%
Back Pain: 6 people, 66.67%
Bone Loss: 5 people, 55.56%
Hyperlipidaemia (presence of excess lipids in the blood): 5 people, 55.56%

Common conditions people have *:

Breast Cancer: 5 people, 55.56%
Cervix Carcinoma (cancer of cervix): 1 person, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Triphasil-21 and have Oral candidiasis?

Check whether Oral candidiasis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Oral candidiasis and when was it recovered:

Oral candidiasis in Triphasil-21

Expand to all the drugs that have ingredients of ethinyl estradiol; levonorgestrel:

Oral candidiasis and drugs with ingredients of ethinyl estradiol; levonorgestrel

Alternative drugs to, pros and cons of Triphasil-21:

Triphasil-21 (533 reports)

Oral candidiasis treatments and more:

Oral candidiasis (17,214 reports)

COVID vaccines that are related to Oral candidiasis:

Common drugs associated with Oral candidiasis:

All the drugs that are associated with Oral candidiasis:

Oral candidiasis (1,747 drugs)

Common conditions associated with Oral candidiasis:

Rheumatoid arthritis: 1,070 reports
Asthma: 881 reports
High blood pressure: 625 reports
Chronic obstructive pulmonary disease: 605 reports
Psoriasis: 512 reports
Pain: 411 reports
Multiple myeloma: 409 reports
Osteoporosis: 407 reports

All the conditions that are associated with Oral candidiasis:

Oral candidiasis (1,151 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ethinyl estradiol; levonorgestrel (the active ingredients of Triphasil-21) and Triphasil-21 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.